pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Revatio
drug
save

Revatio

Marketedupdated 3mo ago
by $VTRS Viatris Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 7
  • tagApproval2 co-mentions · 1 sources
  • drugVYBRIQUE2 co-mentions · 1 sources
  • drugASP-001.11 co-mentions · 1 sources
  • drugViagra1 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources
  • drugsildenafil citrate SR1 co-mentions · 1 sources
  • drugsildenafil citrate1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 30 investigational indications.

all catalysts(1)

approval · 1
Dec 16, 2025
approval
8mo ago
VYBRIQUE (SILDENAFIL CITRATE) — FDA approval
Revatio
→

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 16, 2028
~2.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

  • Dec 24, 2038formulationUS 11337979
  • Dec 24, 2038formulationUS 11464778
  • Dec 24, 2038formulationUS 11759468
  • Dec 24, 2038formulationUS 12005062
  • Dec 24, 2038formulationUS 12186321
  • Dec 16, 2033formulationUS 11123287
  • Dec 16, 2033formulationUS 11123287
  • Dec 16, 2033formulationUS 11123287
  • Dec 16, 2033formulationUS 11123287

FDA exclusivities (8)

  • Jan 31, 2030ODE-469Orphan Drug (7y)3.5y
  • Dec 16, 2028NPNP2.3y
  • Dec 16, 2028NPNP2.3y
  • Dec 16, 2028NPNP2.3y
  • Dec 16, 2028NPNP2.3y
  • Jan 31, 2026M-287Method (3y)
  • Jan 31, 2026M-287Method (3y)
  • Jan 31, 2026M-287Method (3y)

News(0)

no news has mentioned this drug yet

brand
Revatio
generic
sildenafil citrate
MOA
Phosphodiesterase 5A inhibitor
indication
Pulmonary Arterial Hypertension
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?